Literature DB >> 22286808

Genetic syndromes associated with renal cell carcinoma: a review.

Katerina Azeem1, Helena Kollarova, Dagmar Horakova, Silvie Magnuskova, Vladimir Janout.   

Abstract

AIMS: A review of recent knowledge on heredital syndromes related to renal cell carcinoma.
METHODS: Aim of this review was to summarize the recent knowledge of genetic syndromes associated with renal cell carcinoma.
RESULTS: Summary of incidence and factors modulating risk of hereditary renal cell carcinoma development.
CONCLUSIONS: Hereditary forms of RCC are relatively rare. Their study is beneficial in many ways. In individuals at a higher risk of a hereditary syndrome, the knowledge of hereditary forms may help to significantly decrease the impact of the hereditary disease. In the general population, knowledge acquired by the study of hereditary forms of RCC may in the future contribute to both diagnosis and treatment of sporadic tumours.

Entities:  

Mesh:

Year:  2011        PMID: 22286808     DOI: 10.5507/bp.2011.029

Source DB:  PubMed          Journal:  Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub        ISSN: 1213-8118            Impact factor:   1.245


  3 in total

1.  Demethylation drug 5-Aza-2'-deoxycytidine-induced upregulation of miR-200c inhibits the migration, invasion and epithelial-mesenchymal transition of clear cell renal cell carcinoma in vitro.

Authors:  Juan Jiang; B O Yi; Siqing Ding; Jian Sun; Wei Cao; Mengzi Liu
Journal:  Oncol Lett       Date:  2016-03-22       Impact factor: 2.967

2.  LncRNAs expression signatures of renal clear cell carcinoma revealed by microarray.

Authors:  Gan Yu; Weimin Yao; Ji Wang; Xin Ma; Wei Xiao; Heng Li; Ding Xia; Yang Yang; Kangli Deng; Haibing Xiao; Bohan Wang; Xiaolin Guo; Wei Guan; Zhiquan Hu; Yinqi Bai; Hua Xu; Jihong Liu; Xu Zhang; Zhangqun Ye
Journal:  PLoS One       Date:  2012-08-06       Impact factor: 3.240

3.  MicroRNA-21 stimulates epithelial-to-mesenchymal transition and tumorigenesis in clear cell renal cells.

Authors:  Jian Cao; Jun Liu; Ran Xu; Xuan Zhu; Lei Liu; Xiaokun Zhao
Journal:  Mol Med Rep       Date:  2015-11-13       Impact factor: 2.952

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.